Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
SHJBF's 9-Day RSI is ranked worse than 77.14% of 1422
companies
in the Biotechnology industry
Industry Median: 43.225
vs SHJBF: 100.00
Shanghai Junshi Biosciences Co (OTCPK:SHJBF) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Shanghai Junshi Biosciences Co 9-Day RSI Related Terms
SHJBF vs VRTX, REGN, ALNY: 9-Day RSI Comparison
For the Biotechnology subindustry, Shanghai Junshi Biosciences Co's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Junshi Biosciences Co 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Junshi Biosciences Co's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Shanghai Junshi Biosciences Co's 9-Day RSI falls into.
Shanghai Junshi Biosciences Co (OTCPK:SHJBF) 9-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Junshi Biosciences Co (SHJBF) has a 9-Day RSI of 100.00 as of Jul. 21, 2026. According to the industry distribution chart, Shanghai Junshi Biosciences Co ranks #1097 out of 1422 companies in the Biotechnology industry, placing it in the top 77.1%.
Is Shanghai Junshi Biosciences Co's 9-Day RSI too high?
Shanghai Junshi Biosciences Co's current 9-Day RSI is 100.00. The Biotechnology industry median 9-Day RSI is 43.23. Shanghai Junshi Biosciences Co's value of 100.00 is 131.3% above this industry median. Based on the distribution chart, Shanghai Junshi Biosciences Co ranks #1097 out of 1422 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Shanghai Junshi Biosciences Co has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai Junshi Biosciences Co's 9-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Junshi Biosciences Co ranks #1097 out of 1422 companies for 9-Day RSI. This places Shanghai Junshi Biosciences Co in the lower half of its industry. The industry median 9-Day RSI is 43.23. Shanghai Junshi Biosciences Co's value of 100.00 is 131.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 43.23, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Junshi Biosciences Co's current 9-Day RSI of 100.00 is 131.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 43.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Junshi Biosciences Co's current 9-Day RSI is 100.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Junshi Biosciences Co stock overvalued right now?
Shanghai Junshi Biosciences Co (SHJBF) has a current 9-Day RSI of 100.00. The stock's GF Value™ is $5.31, compared to a current price of $3.35 — trading 36.9% below its estimated fair value. The current 9-Day RSI is 100.00 and 131.3% above the Biotechnology industry median of 43.23. Shanghai Junshi Biosciences Co's overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Shanghai Junshi Biosciences Co (SHJBF), the current 9-Day RSI is 100.00 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Junshi Biosciences Co (SHJBF) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Junshi Biosciences Co stock appears to be undervalued.
The current stock price of $3.35 is trading 36.9% below its estimated GF Value™ of $5.31.
Key valuation signals for SHJBF:
9-Day RSI: 100.00
GF Value™: $5.31 vs. price of $3.35 (36.9% below fair value)
Industry Position: 131.3% above the Biotechnology median (#1097 of 1422)
No single metric tells the full story. See the SHJBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Junshi Biosciences Co Business Description
Shanghai Junshi Biosciences Co Ltd is mainly involved in the discovery, development, and commercialisation of therapeutic drugs. It focuses on the development and commercialization of several kinds of drugs, ranging from monoclonal antibodies to various drug modalities, including small molecules, ADCs, bi-specific or multi-specific antibodies, fusion proteins, nucleic acid drugs, and vaccines, as well as the exploration of next-generation therapies, including those for cancer and autoimmune diseases. The Group's portfolio includes commercialized drugs such as Tuoyi, Junmaikang, Mindewei, and Junshida, as well as products in clinical studies or in the marketing application stage. Geographically, it derives maximum revenue from Mainland China, and the rest from USA, India, and other markets.
72GF Score
Get the complete analysis for SHJBF
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHJBF has been successfully added to your 
